Baird raised the firm’s price target on Climb Bio (CLYM) to $12 from $9 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM:
- Climb Bio initiated with an Outperform at Wedbush
- Climb Bio reports Q4 EPS (26c), consensus (21c)
- Climb Bio initiated with an Overweight at Piper Sandler
- Ten new option listings and two option delistings on January 22nd
- Climb Bio’s CLYM116 Moves Into First-in-Human Testing: What Early Investors Should Watch